Your selection

Innovation / 09.08.2021
Eckert & Ziegler Receives Manufacturing Authorization for Thorium and Lutetium Compounds

Eckert & Ziegler Radiopharma GmbH in Braunschweig, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has now received manufacturing authorization from the Lower Saxony authorities for several thorium and lutetium compounds in accordance with the German Medicines Act. This authorization enables Eckert & Ziegler to supply its customers in the pharmaceutical industry with therapeutic radioisotopes for clinical trials and beyond. The radioisotopes are the central active ingredients in a series of innovative cancer drugs that are currently being tested in advanced phases by numerous drug manufacturers.

Obtaining the manufacturing authorization also entitles the Eckert & Ziegler Group to milestone payments for successful technology developments. The profits from these milestones, however, have already been accounted for in the recently updated guidance for 2021.

“Due to the large number of studies in which lutetium-177 is being clinically tested worldwide, we expect an increasing demand for this isotope and related services in the coming years. With the new technology and production facilities in Europe, Asia, and North America, we see ourselves as being excellently positioned to meet this demand," explained Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG.

Radiotherapeutic agents that are coupled with lutetium-177 prior to injection are currently under development for several types of cancer. Lutetium-177-based drugs for the treatment of metastatic prostate cancer are already in the clinical phase III trials. Therapeutic agents for other tumor types are also awaiting approval. In addition to its efficiency, the advantage of lutetium treatment is that it can be coupled with very precise diagnostics. The carrier substance of the therapeutic agent can be linked to a diagnostic radioisotope, for example gallium-68. Using special devices, so-called PET scanners, the response rate for the patient and thus the usefulness of treatment can be predicted with high precision in advance.

Overview News

News Buch Berlin

How to fill a heart

Heart failure with preserved ejection fraction was previously considered largely untreatable. An MDC team led by Professor Michael Gotthardt has now succeeded for the first time in improving cardiac f...

more ...

Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application

Eckert & Ziegler Group is pleased to announce their partnership today with the Canadian Molecular Imaging Probe Consortium (CanProbe), a leader in the advancement and commercialization of novel radiop...

more ...

Genome folding in the mouse brain

A team led by MDC researcher Ana Pombo has deciphered the 3D structure of the genome in three cell types of the mouse brain.

more ...

Events Buch Berlin

10.12.2021, 16:00
Karower Weihnachtsfreude - Überraschungen zur Adventszeit

11.12.2021, 10:00
Gesundheitswandern von Buch bis zur Aussichtsplattform Lietzengraben

Wanderung von ca. 7 km mit längeren Pausen, Picknick und Bewegungsübungen

more ...

11.12.2021, 19:00
Lesung im Trichter: Weihnachten kommt! ...eher als du denkst.

Eine sehr stille Heilige Nacht von und mit Pierre Sanoussi-Bliss

more ...

This website is supported by: